PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
Despite reports on the efficacy of proprotein convertase subtilisin-Kexin type 9 (PCSK9) inhibitors as a potent lipid-lowering agent in various large-scale clinical trials, the anti-atherogenic properties of PCSK9 inhibitors in reducing PCSK9 and atherogenesis biomarkers via the NF-ĸB and eNOS pathw...
| Published in: | International Journal of Molecular Sciences |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Published: |
Multidisciplinary Digital Publishing Institute (MDPI)
2023
|
| Online Access: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85151108307&doi=10.3390%2fijms24065098&partnerID=40&md5=e7b5b09597e9e11e3eedf88a5e7fe36e |